GB0318422D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB0318422D0
GB0318422D0 GBGB0318422.3A GB0318422A GB0318422D0 GB 0318422 D0 GB0318422 D0 GB 0318422D0 GB 0318422 A GB0318422 A GB 0318422A GB 0318422 D0 GB0318422 D0 GB 0318422D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0318422.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0318422.3A priority Critical patent/GB0318422D0/en
Publication of GB0318422D0 publication Critical patent/GB0318422D0/en
Priority to US10/566,842 priority patent/US7989460B2/en
Priority to BRPI0413284-0A priority patent/BRPI0413284A/pt
Priority to EP04743664A priority patent/EP1658280A1/en
Priority to CA002534811A priority patent/CA2534811A1/en
Priority to CN2004800290795A priority patent/CN1863794B/zh
Priority to JP2006522400A priority patent/JP4890249B2/ja
Priority to AU2004263360A priority patent/AU2004263360A1/en
Priority to MXPA06001395A priority patent/MXPA06001395A/es
Priority to PCT/GB2004/003376 priority patent/WO2005014582A1/en
Priority to KR1020067002540A priority patent/KR20060058705A/ko
Priority to IL173484A priority patent/IL173484A0/en
Priority to ZA200601025A priority patent/ZA200601025B/en
Priority to NO20060650A priority patent/NO20060650L/no
Priority to US13/164,310 priority patent/US20120046300A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB0318422.3A 2003-08-06 2003-08-06 Chemical compounds Ceased GB0318422D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB0318422.3A GB0318422D0 (en) 2003-08-06 2003-08-06 Chemical compounds
KR1020067002540A KR20060058705A (ko) 2003-08-06 2004-08-05 혈관형성 억제제로서의 퀴나졸린 유도체
JP2006522400A JP4890249B2 (ja) 2003-08-06 2004-08-05 血管新生阻害剤としてのキナゾリン誘導体
MXPA06001395A MXPA06001395A (es) 2003-08-06 2004-08-05 Derivados de quinazolina en la forma de inhibidores de angiogenesis.
EP04743664A EP1658280A1 (en) 2003-08-06 2004-08-05 Quinazoline derivatives as angiogenesis inhibitors
CA002534811A CA2534811A1 (en) 2003-08-06 2004-08-05 Quinazoline derivatives as angiogenesis inhibitors
CN2004800290795A CN1863794B (zh) 2003-08-06 2004-08-05 作为血管生成抑制剂的喹唑啉衍生物
US10/566,842 US7989460B2 (en) 2003-08-06 2004-08-05 Quinazoline derivatives as angiogenesis inhibitors
AU2004263360A AU2004263360A1 (en) 2003-08-06 2004-08-05 Quinazoline derivatives as angiogenesis inhibitors
BRPI0413284-0A BRPI0413284A (pt) 2003-08-06 2004-08-05 composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou de um sal deste farmaceuticamente aceitável, e, método para produzir um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente
PCT/GB2004/003376 WO2005014582A1 (en) 2003-08-06 2004-08-05 Quinazoline derivatives as angiogenesis inhibitors
IL173484A IL173484A0 (en) 2003-08-06 2006-01-31 Quinazoline derivatives as angiogenesis inhibitors
ZA200601025A ZA200601025B (en) 2003-08-06 2006-02-03 Quinazoline derivatives as angiogenesis inhibitors
NO20060650A NO20060650L (no) 2003-08-06 2006-02-09 Kinazolinderivater som angiogeneseinhibitorer
US13/164,310 US20120046300A1 (en) 2003-08-06 2011-06-20 Quinazoline Derivatives as Angiogenesis Inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0318422.3A GB0318422D0 (en) 2003-08-06 2003-08-06 Chemical compounds

Publications (1)

Publication Number Publication Date
GB0318422D0 true GB0318422D0 (en) 2003-09-10

Family

ID=27839732

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0318422.3A Ceased GB0318422D0 (en) 2003-08-06 2003-08-06 Chemical compounds

Country Status (14)

Country Link
US (2) US7989460B2 (enExample)
EP (1) EP1658280A1 (enExample)
JP (1) JP4890249B2 (enExample)
KR (1) KR20060058705A (enExample)
CN (1) CN1863794B (enExample)
AU (1) AU2004263360A1 (enExample)
BR (1) BRPI0413284A (enExample)
CA (1) CA2534811A1 (enExample)
GB (1) GB0318422D0 (enExample)
IL (1) IL173484A0 (enExample)
MX (1) MXPA06001395A (enExample)
NO (1) NO20060650L (enExample)
WO (1) WO2005014582A1 (enExample)
ZA (1) ZA200601025B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
EP1370553B1 (en) * 2001-03-23 2006-05-10 Bayer Corporation Rho-kinase inhibitors
CN1625555A (zh) * 2002-02-01 2005-06-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
WO2006040520A1 (en) 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
CL2007003158A1 (es) * 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
RU2010120671A (ru) * 2007-10-24 2011-11-27 Мерк Шарп Энд Домэ Корп. (Us) Гетероциклические фениламидные антагонисты кальциевых каналов т-типа
US8211911B2 (en) * 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
ES2831625T3 (es) * 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
USD746538S1 (en) * 2014-02-03 2015-12-29 Nautilus Hyosung Inc. Automated teller machine
USD746539S1 (en) * 2014-03-24 2015-12-29 Nautilus Hyosung Inc. Automated teller machine
USD765340S1 (en) * 2014-03-24 2016-08-30 Nautilus Hyosung Inc. Automated teller machine
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
WO2020057403A1 (zh) * 2018-09-18 2020-03-26 北京越之康泰生物医药科技有限公司 吲哚衍生物及其在医药上的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
MXPA02012943A (es) * 2000-08-09 2003-05-15 Astrazeneca Ab Compuestos de cinolina.
AU2001292137A1 (en) * 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives
EP1332141A1 (en) * 2000-10-25 2003-08-06 AstraZeneca AB Quinazoline derivatives
ES2272737T3 (es) * 2001-07-16 2007-05-01 Astrazeneca Ab Derivados de quinolina y su uso como inhibidores de tirosina quinasas.
WO2003048159A1 (en) * 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
CN1625555A (zh) * 2002-02-01 2005-06-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
EP1971338B8 (en) * 2005-12-22 2011-09-21 AstraZeneca AB Combination of zd6474 and pemetrexed

Also Published As

Publication number Publication date
CN1863794A (zh) 2006-11-15
KR20060058705A (ko) 2006-05-30
NO20060650L (no) 2006-04-24
CN1863794B (zh) 2012-04-25
MXPA06001395A (es) 2006-05-19
US20120046300A1 (en) 2012-02-23
US20080058342A1 (en) 2008-03-06
JP4890249B2 (ja) 2012-03-07
EP1658280A1 (en) 2006-05-24
US7989460B2 (en) 2011-08-02
IL173484A0 (en) 2006-06-11
AU2004263360A1 (en) 2005-02-17
BRPI0413284A (pt) 2006-10-10
JP2007501210A (ja) 2007-01-25
CA2534811A1 (en) 2005-02-17
ZA200601025B (en) 2007-05-30
WO2005014582A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
GB0317009D0 (en) Chemical compounds
GB0304194D0 (en) Chemical compounds
GB0308208D0 (en) Chemical compounds
GB0319124D0 (en) Chemical compounds
GB0311276D0 (en) Chemical compounds
GB0319126D0 (en) Chemical compounds
GB0315203D0 (en) Chemical compounds
EP1648448A4 (en) CHEMICAL COMPOUNDS
GB0311274D0 (en) Chemical compounds
EP1590339A4 (en) CHEMICAL COMPOUNDS
GB0319759D0 (en) Chemical compounds
GB0318422D0 (en) Chemical compounds
GB0318423D0 (en) Chemical compounds
EP1654251A4 (en) CHEMICAL COMPOUNDS
GB0308801D0 (en) Chemical compounds
GB0319690D0 (en) Chemical compounds
GB0310724D0 (en) Chemical compounds
GB0306358D0 (en) Chemical compounds
GB0306357D0 (en) Chemical compounds
GB0304723D0 (en) Chemical compounds
GB0310464D0 (en) Chemical compounds
GB0319149D0 (en) Chemical compounds
GB0315872D0 (en) Chemical compounds
GB0306454D0 (en) Chemical compounds
GB0314246D0 (en) Chemical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)